Lintuzumab
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells. Trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival.
Link from a Wikipage to another Wikipage
primaryTopic
Lintuzumab
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells. Trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival.
has abstract
Il lintuzumab o SGN-33 è un an ...... le sindromi mielodisplastiche.
@it
Lintuzumab (SGN-33) is a human ...... ith myelodysplastic syndromes.
@en
لينتوزوماب جسم مضاد وحيد النسي ...... لاج أمراض التكاثر النقوية هذه.
@ar
CAS number
166089-32-3
FDA UNII code
V00Y10W60W
Wikipage page ID
page length (characters) of wiki page
Wikipage revision ID
984,386,993
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
mab type
mab
@en
source
zu/o
@en
target
type
mab
@en
UNII
V00Y10W60W
@en
Verifiedfields
changed
@en
verifiedrevid
458,270,010
wikiPageUsesTemplate
hypernym
comment
Il lintuzumab o SGN-33 è un an ...... n aumento della sopravvivenza.
@it
Lintuzumab (SGN-33) is a human ...... ed to show increased survival.
@en
لينتوزوماب جسم مضاد وحيد النسي ...... لاج أمراض التكاثر النقوية هذه.
@ar
label
Lintuzumab
@en
Lintuzumab
@it
لينتوزوماب
@ar